Control Bionics (ASX:CBL) delivers solid March quarter with 90% jump in US sales

In the third quarter ended 31 March 2022, CBL sales through North American operations were recorded at AU$0.95 million. In the North American market alone, the company marked striking growth of 90% year-on-year in unit sales.

The ASX-listed company has been able to nail down its sales and expansion targets, on the back of its evolving suite of AAC (augmentative and alternative communication) solutions with the changing needs of the users.


  • Control Bionics witnessed 90% growth in North America unit sales in Q3 FY22.
  • The company is geared up to launch its NeuroNode technology into the Japanese market.
  • CBL made significant investments in March quarter across divisions, aiming high sales growth and productivity gains.
  • The Company had a cash balance of AU$6.9 million at March end.

You'll Also Like